Literature DB >> 11328282

The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation.

R Fuge1, J M Bird, A Fraser, D Hart, L Hunt, J M Cornish, N Goulden, A Oakhill, D H Pamphilon, C G Steward, D I Marks.   

Abstract

In this study, we retrospectively analysed the clinical features, risk factors and outcome of 22 patients with thrombotic thrombocytopenic purpura (TTP) occurring after allogeneic stem cell transplantation. All but two of these patients received stem cells from unrelated donors (UDs), two-thirds were female, three-quarters were adults and leukaemia was the major reason for transplant. The incidence of TTP was 20 out of 332 patients (6%) with UD transplants and two out of 104 recipients (2%) of matched sibling allografts (P = 0.16). In order to ascertain basic demographic risk factors for the development of TTP, we compared the 22 patients with 434 patients who did not develop TTP. Compared with patients who did not develop TTP, patients with TTP were nearly three times older (P < 0.001) and were more than twice as likely to be female (P = 0.001). Because > 90% of patients were recipients of UD marrow, we then compared the 20 UD-bone marrow transplantation (BMT) patients with 60 randomly selected UD-BMT patients who did not develop TTP. On univariate analysis, age and female gender were again significant risk factors, as was grade II-IV acute graft-versus-host disease (GvHD) (P = 0.002), and there was a trend towards an association with chronic GvHD (P = 0.083). However, after logistic regression analysis, only age and sex remained significant (P < 0.001 and 0.009 respectively). We report an 86% mortality with only three survivors out of 22 patients, and one of these remains thrombocytopenic and red cell transfusion dependent, possibly in part because of graft hypoplasia. Six out of 17 patients responded to plasmapheresis, but the majority of them ultimately succumbed because of TTP, often in association with GvHD or fungal infection.

Entities:  

Mesh:

Year:  2001        PMID: 11328282     DOI: 10.1046/j.1365-2141.2001.02699.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.

Authors:  Michelle Schoettler; Christine Duncan; Leslie Lehmann
Journal:  Pediatr Transplant       Date:  2019-03-03

Review 2.  Renal dysfunction following bone marrow transplantation.

Authors:  Stephan Kemmner; Mareike Verbeek; Uwe Heemann
Journal:  J Nephrol       Date:  2016-09-02       Impact factor: 3.902

3.  Clinical significance of fragmented red cells after allogeneic bone marrow transplantation.

Authors:  Heiwa Kanamori; Yumiko Takaishi; Maki Takabayashi; Masatsugu Tanaka; Satoshi Yamaji; Naoto Tomita; Katsumichi Fujimaki; Shin Fujisawa; Shinichiro Watanabe; Michio Matsuzaki; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

4.  Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease.

Authors:  Yasunobu Ishikawa; Saori Nishio; Hiroaki Sasaki; Risshi Kudo; Hideki Goto; Masanori Ito; Akira Suzuki; Yuichiro Fukazawa; Toshio Mochizuki; Takao Koike
Journal:  Clin Exp Nephrol       Date:  2010-12-01       Impact factor: 2.801

Review 5.  Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1.

Authors:  Jeffrey S Upperman; Jacques Lacroix; Martha A Q Curley; Paul A Checchia; Daniel W Lee; Kenneth R Cooke; Robert F Tamburro
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 6.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

7.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Authors:  Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

8.  Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.

Authors:  Sepideh Shayani; Joycelynne Palmer; Tracey Stiller; Xueli Liu; Sandra H Thomas; Tam Khuu; Pablo M Parker; Samer K Khaled; Stephen J Forman; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-15       Impact factor: 5.742

Review 9.  Post-bone marrow transplant thrombotic microangiopathy.

Authors:  F Obut; V Kasinath; R Abdi
Journal:  Bone Marrow Transplant       Date:  2016-03-14       Impact factor: 5.483

Review 10.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.